Homocysteine, folate, and congenital heart defects.
Congenital heart disease will be the next frontier for prevention by periconceptional management of homocysteine and its metabolites by folate supplementation. Evidence for the connection between maternal and fetal folate metabolism and congenital malformations of the cardiovascular system is reviewed including possible applications to the large population of patients at risk for a child with congenital heart disease.
Huhta
James C
JC
University of South Florida College of Medicine, St. Petersburg, Florida 33701, USA. jhernand@hsc.usf.edu
Hernandez-Robles
Jose A
JA
D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D005492:Folic Acid / Q000378:metabolism*; D005494:Folic Acid Deficiency / Q000150:complications* / Q000151:congenital; D006330:Heart Defects, Congenital / Q000209:etiology*; D006710:Homocysteine / Q000378:metabolism*; D006801:Humans; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D051379:Mice; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic
D006710:Homocysteine; D005492:Folic Acid; D042965:Methylenetetrahydrofolate Reductase (NADPH2)